Effect of a short course of neoadjuvant hormonal therapy on the response to subsequent androgen suppression in prostate cancer patients with relapse after radiotherapy: a secondary analysis of the randomized protocol RTOG 86-10.

What Was Tested

The paper reports a study of Goserelin and Flutamide, published as a randomized controlled trial.

Who Took Part

The abstract describes 456 patients taking part.

The age groups tagged for this paper are middle-aged adults, older adults and people over 80, men only.

The overall and disease-specific survival after both randomization and salvage HT for patients with relapse was evaluated, as well as the duration of response in those patients undergoing salvage HT.

The outcomes in patients who had received neoadjuvant HT vs. those who had not were compared.

How the Study Was Run

The researchers set it up as a randomized study.

Because people in this Goserelin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

The median follow-up after randomization for all alive patients was 9.0 years and was 5.5 years for alive patients after beginning salvage HT.

What Was Measured

Topics PubMed links to this paper include Antineoplastic Agents, Hormonal, Chemotherapy, Adjuvant, Disease-Free Survival, Flutamide, Goserelin, Prostatic Neoplasms and Recurrence.

What This Means in Plain Language

The paper is a randomized study of Goserelin and Flutamide in 456 patients.

With several hundred people or more, it is a fairly large study for this kind of research.

Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2002 (International journal of radiation oncology, biology, physics), a journal based in United States.

More context: the related Goserelin library page, all human trials.